Medications

Antibody eradicates leukemia stem cells

The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80 percent of people with CML who received the drug, the disease went into complete ...

Diseases, Conditions, Syndromes

New window on fibrosis

DDR1 is a receptor tyrosine kinase (RTK)—a cell surface receptor—that regulates multiple functions including the maintenance of the normal structure of tissues, but which also contributes to pathological conditions including ...

Neuroscience

AAN: Oral BTK inhibitor superior to placebo in multiple sclerosis

(HealthDay)—The selective Bruton's tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis, ...

Oncology & Cancer

At molecular level, cancer mutations echo Darwin's observations

There are more than 100 mutations of the protein behind the deadly brain cancer, glioblastoma, however an international research team has discovered something these mutations have in common. The new understanding could lead ...

Oncology & Cancer

Reasons for TKI discontinuation ID'd in chronic myeloid leukemia

(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...

page 1 from 23